(ALT) Altimmune - Ratings and Ratios

Altimmune, Inc. (NASDAQ:ALT) is a clinical-stage biopharmaceutical company specializing in the development of innovative treatments for obesity and liver diseases. The companys lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist currently in Phase 2 clinical trials for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (NASH). This dual-acting mechanism targets multiple pathways involved in weight loss and metabolic improvement, positioning pemvidutide as a potential competitor in the growing obesity therapeutics market. Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate in Phase 2 clinical trials for chronic hepatitis B infection, aiming to address the significant unmet need for effective treatments in this patient population. The company, originally founded in 1997 as Vaxin Inc., rebranded as Altimmune, Inc. in 2015 and is headquartered in Gaithersburg, Maryland, a hub for biotechnology innovation.

From a technical perspective, ALT shares are trading near key moving averages, with the 20-day SMA at $6.49 and the 50-day SMA at $7.02, suggesting a potential range-bound trading pattern in the near term. The average trading volume of 2.13 million shares over the past 20 days indicates moderate liquidity. The ATR of $0.41 reflects relatively low volatility compared to other biotechnology stocks.

Fundamentally, Altimmunes market capitalization stands at $471.56 million, with a price-to-book ratio of 3.62, indicating investor confidence in the companys pipeline and growth prospects. The lack of positive earnings (P/E: 0.00) is typical for a clinical-stage biotech firm focused on R&D. The extremely high P/S ratio of 9068.39 highlights the markets expectation of significant future revenue growth, though this is speculative given the current pre-revenue stage of the company.

3-Month Forecast: Based on the provided data, ALT shares are likely to trade within a narrow range near the 20-day and 50-day SMAs ($6.49 - $7.02). The stock may experience volatility driven by clinical trial updates or broader market sentiment toward biotechnology stocks. The high P/S ratio suggests investor optimism about the companys pipeline, but the lack of profitability (RoE: -77.61%) underscores the speculative nature of the investment. Technical support near $6.00 and resistance near $7.50 are key levels to monitor.